Co-founder and CSO at PhAST and Professor at ETH Zurich
PhAST
PhAST Diagnostics develops rapid diagnostic technology that utilizes advanced pathogen detection methods to deliver timely and actionable results. This technology addresses the critical need for swift identification of infectious agents, enabling healthcare providers to make informed treatment decisions.
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Raised to date
$3.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current diagnostic methods for infectious diseases often suffer from slow turnaround times, limiting the ability of healthcare providers to make immediate and informed treatment decisions. Delays in pathogen identification can lead to inappropriate antibiotic use, increased healthcare costs, and poorer patient outcomes.
Solution
PhAST Diagnostics is developing rapid diagnostic technology designed for the swift identification of infectious agents, providing actionable results in a timely manner. Their approach aims to accelerate the diagnostic process, enabling healthcare providers to make informed decisions more quickly. By reducing the time required for pathogen detection, PhAST Diagnostics seeks to improve patient care, reduce unnecessary antibiotic use, and lower healthcare costs associated with delayed diagnoses.
Target Audience
The primary audience includes healthcare providers who require rapid and accurate diagnostic information to make informed treatment decisions for patients with infectious diseases.
Features
- Advanced pathogen detection methods for rapid identification of infectious agents
- Technology designed to deliver timely and actionable results